Nicole Junkermann, NJF Capital founder, presents Owkin, an AI medical research start-up whose mission is to use machine learning to develop better drugs for patients. Junkermann has invested in Owkin alongside Brent Hobermann, and they are passionate about the healthcare sector and its growing use of biotech.
OWKIN is calling for partners to engage in collaborative research to develop effective treatments for Covid-19.
The Covid-19 Open AI Consortium (COAI) will unite academic institutions, researchers, data scientists and industrial partners.
It’s a response to healthcare systems being overwhelmed as they cope with the crisis.
They lack the resources and methodology to assess disease evolution, improve treatment and anticipate bottlenecks.
AI models, built on clinical and demographic data can help by predicting challenging scientific questions including prognosis and treatment response.
The first live research area will explore the role of cardiovascular complications like high blood pressure in Covid-19 patients.
All machine learning models developed within COAI will be open-sourced and shared with the global medical and scientific community.